136117-73-2

Usage

Uses

Used in Pharmaceutical Industry:
Imidazo[1,2-a]pyridine-7-carboxaldehyde (9CI) is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of compounds with potential biological activities, such as antitumor and anti-inflammatory properties. This makes it a valuable component in the creation of new drugs for the treatment of various diseases.
Used in Agrochemical Industry:
In the agrochemical sector, Imidazo[1,2-a]pyridine-7-carboxaldehyde (9CI) serves as a building block for the synthesis of agrochemicals. Its incorporation into these products can lead to the development of new pesticides or herbicides with improved efficacy and selectivity, contributing to more effective crop protection.
Used in Organic Synthesis:
Imidazo[1,2-a]pyridine-7-carboxaldehyde (9CI) is also employed as a versatile building block in organic synthesis. Its structural features and potential reactivity enable the creation of complex molecules and functional materials for various applications across different industries. This includes the development of new compounds for use in materials science, chemical research, and other specialized fields.

Upstream product

• 86718-01-6 methyl 7-imidazo<1,2-a>pyridinecarboxylate 

Downstream Products

• 1141505-08-9 1-[3-(7-acetyl-imidazo[1,2-a]pyridin-3-yl)-phenyl]-3-(2,2,2-trifluoro-ethyl)-urea 
• 1141505-26-1 1-[3-(7-cyclopropanecarbonyl-imidazo[1,2-a]pyridin-3-yl)-phenyl]-3-(2,2,2-trifluoro-ethyl)-urea 
• 1316087-80-5 1-[3-(7-{1-Hydroxyimino-ethyl}-imidazo[1,2-a]pyridin-3-yl)-phenyl]-3-(2,2,2-trifluoro-ethyl)-urea 
• 1251899-91-8 1-[3-(7-{Cyclopropyl-[(E)-2-hydroxyethoxyimino]-methyl}-imidazo[1,2-a]pyridin-3-yl)-5-isopropoxy-phenyl]-3-(2,2,2-trifluoro-ethyl)-urea 
• 1251899-57-6 1-[3-(7-{Cyclopropyl-[(E)-hydroxyimino]-methyl}-imidazo[1,2-a]pyridin-3-yl)-5-isopropoxy-phenyl]-3-(2,2,2-trifluoro-ethyl)-urea 
• 1251899-88-3 1-[3-(7-{(E)-1-2-hydroxyethoxyiminoethyl}imidazo[1,2-a]pyridin-3-yl)phenyl]-3-(2,2,2-trifluoroethyl)urea 
• 1251863-23-6 1-[3-(7-cyclopropanecarbonylimidazo[1,2-a]pyridin-3-yl)-5-isopropoxyphenyl]-3-(2,2,2-trifluoroethyl)urea 
• 1251900-04-5 C₃₁H₄₂F₃N₅O₄Si 
• 1251899-76-9 1-[3-(7-{cyclopropylhydroxyiminomethyl}imidazo[1,2-a]pyridin-3-yl)phenyl]-3-(2,2,2-trifluoroethyl)urea 
• 1036991-50-0 1-(imidazo[1,2-a] pyridin-7-yl)ethan-1-one 
• 372147-64-3 (Z)-ethyl α-[(triphenylphosphoranylidene)amino]-β-(imidazo[1,2-a]piridin-7-yl)propenoate 

Relevant academic research and scientific papers

Imidazo[1,2-a]pyridines. Synthesis and inotropic activity of new 5-imidazo[1,2-a]pyridinyl-2(1H)-pyridinone derivatives

A series of 1,2-dihydro-5-imidazo[1,2-a]pyridinyl-2(1H)-pyridinones was synthesized and evaluated for positive inotropic activity. 1,2-Dihydro-5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-3- pyridinecarbonitrile (11a) hydrochloride monohydrate (E-1020) was found to be a potent and selective inhibitor of phosphodiesterase III and a long-acting, potent, orally active positive inotropic agent. Additional imidazo[1,2-a]pyridin-2-yl (3a), -3-yl (16), -7-yl (20) and -8-yl (24a) compounds were also prepared. Altering the pyridine substitution from the 2-position to the 6-position produced a 2-fold increase in the i.v. cardiotonic potency (ED50) from 52 to 23 μg/kg, while substitution at the 3-, 7- or 8-position reduced potency. In the 2-positional isomers, introduction of halogen groups enhanced the activity and 3-chloro-1,2-dihydro-5-(6-fluoroimidazo[1,2-a]pyridin-2-yl)-6-methyl-2(1H)- pyridinone (3a) was the most potent (i.v. ED50 11 μg/kg) in this seris. E-1020 is presently under development for the treatment of congestive heart failure.